Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 381602, 8 pages
http://dx.doi.org/10.1155/2015/381602
Research Article

TOP2A Amplification and Overexpression in Hepatocellular Carcinoma Tissues

1Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
2Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
3Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
4Division of General Surgery, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

Received 7 August 2014; Accepted 14 December 2014

Academic Editor: Atif A. Ahmed

Copyright © 2015 Ravat Panvichian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, “The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide,” Journal of Hepatology, vol. 45, no. 4, pp. 529–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Parkin, “The global health burden of infection-associated cancers in the year 2002,” International Journal of Cancer, vol. 118, no. 12, pp. 3030–3044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. N. C. Popescu, C. R. King, and M. H. Kraus, “Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32,” Genomics, vol. 4, no. 3, pp. 362–366, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima, and T. Yamamoto, “The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity,” Science, vol. 232, no. 4758, pp. 1644–1646, 1986. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Slamon, W. Eiermann, N. Robert et al., “Adjuvant trastuzumab in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 365, no. 14, pp. 1273–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Nakopoulou, K. Stefanaki, D. Filaktopoulos, and I. Giannopoulou, “C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study,” Histology and Histopathology, vol. 9, no. 4, pp. 677–682, 1994. View at Google Scholar · View at Scopus
  9. T. Heinze, S. Jonas, A. Karsten, and P. Neuhaus, “Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time,” Anticancer Research, vol. 19, no. 4, pp. 2501–2503, 1999. View at Google Scholar · View at Scopus
  10. C. Hsu, C.-L. Huang, H.-C. Hsu, P.-H. Lee, S.-J. Wang, and A.-L. Cheng, “HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity,” Cancer, vol. 94, no. 2, pp. 415–420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Vlasoff, D. Y. Baschinsky, B. R. de Young, C. D. Morrison, G. J. Nuovo, and W. L. Frankel, “C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms,” Applied Immunohistochemistry and Molecular Morphology, vol. 10, no. 3, pp. 237–241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Huang, Z. Y. Zhu, Q. W. Liang, and Y. Fang, “Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular carcinoma and their clinical significance,” Zhonghua Bing Li Xue Za Zhi, vol. 32, no. 1, pp. 20–24, 2003. View at Google Scholar
  13. T.-J. Huang, B.-J. Huang, Q.-W. Liang, C.-W. Huang, and Y. Fang, “Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma,” Hepatobiliary and Pancreatic Diseases International, vol. 3, no. 1, pp. 62–68, 2004. View at Google Scholar · View at Scopus
  14. Z.-H. Xian, S.-H. Zhang, W.-M. Cong, W.-Q. Wu, and M.-C. Wu, “Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma,” The Journal of Clinical Pathology, vol. 58, no. 5, pp. 500–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bacaksiz, F. I. Sahin, B. Bilezikci, and Z. Yilmaz, “Determination of HER-2/Neu status in hepatocellular carcinoma cases,” Genetic Testing, vol. 12, no. 2, pp. 211–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Tsai-Pflugfelder, L. F. Liu, A. A. Liu et al., “Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 19, pp. 7177–7181, 1988. View at Publisher · View at Google Scholar · View at Scopus
  17. P. M. Watt and I. D. Hickson, “Structure and function of type II DNA topoisomerases,” Biochemical Journal, vol. 303, no. 3, pp. 681–695, 1994. View at Google Scholar · View at Scopus
  18. R. J. Isaacs, S. L. Davies, M. I. Sandri, C. Redwood, N. J. Wells, and I. D. Hickson, “Physiological regulation of eukaryotic topoisomerase II,” Biochimica et Biophysica Acta, vol. 1400, no. 1–3, pp. 121–137, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Isaacs, A. L. Harris, and I. D. Hickson, “Regulation of the human topoisomerase IIα gene promoter in confluence- arrested cells,” The Journal of Biological Chemistry, vol. 271, no. 28, pp. 16741–16747, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. F. P. O'Malley, S. Chia, D. Tu et al., “Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy,” Journal of the National Cancer Institute, vol. 101, no. 9, pp. 644–650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Slamon and M. F. Press, “Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers,” Journal of the National Cancer Institute, vol. 101, no. 9, pp. 615–618, 2009. View at Google Scholar
  22. M. F. Press, G. Sauter, M. Buyse et al., “Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 859–867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Wang, B. Xu, P. Yuan et al., “TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy,” Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 531–537, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Watanuki, S. Ohwada, T. Fukusato et al., “Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma,” Anticancer Research, vol. 22, no. 2, pp. 1113–1119, 2002. View at Google Scholar · View at Scopus
  25. N. Wong, W. Yeo, W.-L. Wong et al., “TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance,” International Journal of Cancer, vol. 124, no. 3, pp. 644–652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Panvichian, A. Tantiwetrueangdet, S. Wongwaisayawan, A. Nampoon, P. Lertsithichai, and S. Leelaudomlipi, “HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere,” Applied Immunohistochemistry & Molecular Morphology, vol. 20, no. 4, pp. 367–374, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 118–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Devilee and C. J. Cornelisse, “Somatic genetic changes in human breast cancer,” Biochimica et Biophysica Acta: Reviews on Cancer, vol. 1198, no. 2-3, pp. 113–130, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Van de Vijver, “Molecular genetic changes in human breast cancer,” Advances in Cancer Research, vol. 61, pp. 25–56, 1993. View at Publisher · View at Google Scholar · View at Scopus
  30. T.-J. Song, Y. Fong, S.-J. Cho et al., “Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis,” Journal of Surgical Oncology, vol. 106, no. 1, pp. 84–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. L. Caruso and A. M. Valentini, “Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation,” Anticancer Research, vol. 19, no. 5, pp. 3853–3856, 1999. View at Google Scholar · View at Scopus
  32. Z. Tang, L. Qin, X. Wang et al., “Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: With relation to tumor size and invasiveness,” Chinese Medical Journal, vol. 111, no. 4, pp. 313–318, 1998. View at Google Scholar · View at Scopus
  33. I. O. L. Ng, J. Na, E. C. S. Lai, S. T. Fan, and M. Ng, “Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen,” American Journal of Clinical Pathology, vol. 104, no. 3, pp. 313–318, 1995. View at Google Scholar · View at Scopus
  34. I. O. L. Ng, E. C. S. Lai, S. T. Fan, M. Ng, A. S. Y. Chan, and M. K. P. So, “Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma,” Cancer, vol. 73, no. 9, pp. 2268–2274, 1994. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Scholl, P. Beuzeboc, and P. Pouillart, “Targeting HER2 in other tumor types,” Annals of Oncology, vol. 12, supplement 1, pp. S81–S87, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. T. A. H. Järvinen, M. Tanner, M. Bärlund, Å. Borg, and J. Isola, “Characterization of topoisomerase IIα gene amplification and deletion in breast cancer,” Genes, Chromosomes and Cancer, vol. 26, no. 2, pp. 142–150, 1999. View at Publisher · View at Google Scholar
  37. T. A. H. Järvinen, M. Tanner, V. Rantanen et al., “Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer,” The American Journal of Pathology, vol. 156, no. 3, pp. 839–847, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. T. A. H. Järvinen and E. T. Liu, “HER-2/neu and topoisomerase IIα in breast cancer,” Breast Cancer Research and Treatment, vol. 78, no. 3, pp. 299–311, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Simon, R. Atefy, U. Wagner et al., “HER-2 and TOP2A coamplification in urinary bladder cancer,” International Journal of Cancer, vol. 107, no. 5, pp. 764–772, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Di Leo, D. Gancberg, D. Larsimont et al., “HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil,” Clinical Cancer Research, vol. 8, no. 5, pp. 1107–1116, 2002. View at Google Scholar · View at Scopus
  41. A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone, “Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer,” Clinical Cancer Research, vol. 5, no. 8, pp. 2048–2058, 1999. View at Google Scholar · View at Scopus
  42. M. J. Costa, C. L. Hansen, J. A. Holden, and D. Guinee Jr., “Topoisomerase IIα: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum,” International Journal of Gynecological Pathology, vol. 19, no. 3, pp. 248–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. A. C. Lazaris, N. G. Kavantzas, H. S. Zorzos, N. V. Tsavaris, and P. S. Davaris, “Markers of drug resistance in relapsing colon cancer,” Journal of Cancer Research and Clinical Oncology, vol. 128, no. 2, pp. 114–118, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Fritz, C. M. Cabrera, J. Dippon et al., “c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study,” Breast Cancer Research, vol. 7, no. 3, pp. R374–R384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. M. F. de Resende, S. Vieira, L. T. D. Chinen et al., “Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer,” Journal of Translational Medicine, vol. 11, article 36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Gong, L.-X. Wei, P. Ren et al., “Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma,” PLoS ONE, vol. 9, no. 1, Article ID e87120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Rody, T. Karn, E. Ruckhäberle et al., “Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer,” Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 457–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Tokiniwa, J. Horiguchi, D. Takata et al., “Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer,” Breast Cancer, vol. 19, no. 4, pp. 309–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. R. E. Mueller, R. K. Parkes, I. Andrulis, and F. P. O'Malley, “Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples,” Genes Chromosomes and Cancer, vol. 39, no. 4, pp. 288–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Schindlbeck, D. Mayr, C. Olivier et al., “Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 7, pp. 1029–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Nikolényi, F. Sükösd, L. Kaizer et al., “Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer,” Oncology, vol. 80, no. 3-4, pp. 269–277, 2011. View at Publisher · View at Google Scholar
  52. S. Y. Kanta, T. Yamane, Y. Dobashi, F. Mitsui, K. Kono, and A. Ooi, “Topoisomerase IIα gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study,” Human Pathology, vol. 37, no. 10, pp. 1333–1343, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Srikantan, K. Abdelmohsen, E. K. Lee et al., “Translational control of TOP2A Influences doxorubicin efficacy,” Molecular and Cellular Biology, vol. 31, no. 18, pp. 3790–3801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Gerdes, H. Lemke, and H. Baisch, “Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67,” The Journal of Immunology, vol. 133, no. 4, pp. 1710–1715, 1984. View at Google Scholar · View at Scopus
  55. M. M. S. Heck, W. N. Hittelman, and W. C. Earnshaw, “Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 4, pp. 1086–1090, 1988. View at Publisher · View at Google Scholar · View at Scopus
  56. R. D. Woessner, M. R. Mattern, C. K. Mirabelli, R. K. Johnson, and F. H. Drake, “Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells,” Cell Growth & Differentiation, vol. 2, no. 4, pp. 209–214, 1991. View at Google Scholar · View at Scopus